Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Elahere FDA Approved for Patients with FRα-Positive, Platinum-Resistant Ovarian Cancer

December 2022 Vol 8 No 6

In November 2022, the FDA approved Elahere (mirvetuximab soravtansine-gynx; from ImmunoGen), an FRα inhibitor, for the treatment of adults with FRα-positive platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer after 1 to 3 systemic treatments. Elahere is the first FRα-directed antibody–drug conjugate approved by the FDA.

Patients should be identified for treatment with Elahere by an FDA-approved test that was approved on the same day as this new drug.

Ursula Matulonis, MD
Ursula Matulonis, MD

“The approval of Elahere is significant for patients with FRα-positive platinum-resistant ovarian cancer, which is characterized by limited treatment options and poor outcomes,” said Ursula Matulonis, MD, Chief, Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, and co-principal investigator of the SORAYA study. “Elahere’s impressive anti-tumor activity, durability of response, and overall tolerability observed in SORAYA demonstrate the benefit of this new therapeutic option.”

The FDA approved Elahere based on results of a clinical trial in 106 patients with FRα-positive, platinum-resistant epithelial ovarian cancer. The drug’s safety was evaluated in a pooled analysis of 3 studies that included 464 patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

All patients received Elahere as an IV infusion every 3 weeks, until disease progression or unacceptable side effects. The response to Elahere was evaluated every 6 weeks for the first 36 weeks, and every 12 weeks thereafter.

Among the 104 patients with platinum-resistant epithelial ovarian cancer who received 1 or more doses of Elahere, 31.7% of patients had a response to therapy, including 5 complete responses (no sign of cancer), and the average response lasted 6.9 months.

Elahere is associated with serious ocular side effects that must be carefully monitored. The most common side effects with Elahere were vision problems, dry eye, fatigue, nausea, abdominal pain, decreased lymphocytes, peripheral neuropathy, diarrhea, decreased albumin, constipation, and abnormal laboratory test results.

Recommended For You